SCHEMBL3632867

SCHEMBL3632867

Clc1ccc(Nc2ncc(-c3nc4ccccc4[nH]3)cc2Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.54
MET P08581 5/20 0.54
RAB9A P51151 5/20 0.52
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 4/20 0.52
NPC1 O15118 4/20 0.52
GRM5 P41594 4/20 0.52
HPSE Q9Y251 1/20 0.47
PKM P14618 1/20 0.46
MAPT P10636 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HPGD P15428 3/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 1/20 0.46
RECQL P46063 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
HSD17B10 Q99714 2/20 0.46
USP2 O75604 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3633502 0.86 GRM5 (0.47) KDRMETRAB9AALDH1A1KDM4E
SCHEMBL27801687 0.86 NPC1 (0.48) KDRMETRAB9AALDH1A1KDM4E
SCHEMBL4516647 0.78 GRM5 (0.57) KDRMETGRM5HSD17B10MEN1
SCHEMBL4505307 0.75 GRM5 (0.57) GRM5MAPTLMNAPOLB
SCHEMBL3636743 0.74 GRM5 (0.50) KDRMETRAB9ANPC1GRM5
SCHEMBL197619 0.74 RAB9A (0.72) RAB9AALDH1A1KDM4ENPC1HPSE
SCHEMBL4518773 0.74 GRM5 (0.61) KDRRAB9AALDH1A1NPC1GRM5
SCHEMBL15873609 0.73 GRM5 (0.54) ALDH1A1KDM4EGRM5SMN1; SMN2LMNA
SCHEMBL4508452 0.73 GRM5 (0.50) ALDH1A1KDM4EGRM5LMNAHSD17B10
SCHEMBL4517050 0.72 GRM5 (0.54) GRM5MAPTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146969-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Novartis Ag (CH) 2010-01-27 EP disclosed
US-20090105266-A1 Organic compounds NOVARTIS AG (CH) 2009-04-23 US disclosed
US-20090105266-A1 Organic compounds NOVARTIS AG (CH) 2009-04-23 US disclosed
US-20090105266-A1 Organic compounds NOVARTIS AG (CH) 2009-04-23 US disclosed
WO-2008128968-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 NOVARTIS AG (CH) 2008-10-30 WO disclosed
WO-2008128968-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 NOVARTIS AG (CH) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105266-A1 Organic compounds SLCO2B1, SLCO1B1, SLCO1B3 KDR 4616/4885MET 3827/4885RAB9A 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.